Jynarque tablets 60MG/30MG
Ended Awarded Last action
- Contract number
- 36C24622F0094
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 6
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $136,002
Award facts
- Contract value 100% obligated
- $136,002.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15275, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$1,113 | |
| Supplemental Agreement for work within scope | $13,287 | |
| Original award | $123,827 |
About this award
Otsuka America Pharmaceutical Inc. received a delivery order from the Department of Veterans Affairs Veterans Integrated Service Network 6 (VISN 6) on December 30, 2021, for the supply of Jynarque tablets in 60mg/30mg dosages. This firm fixed-price delivery order, valued at $136,002.04 with an ultimate completion date of May 27, 2022, was issued without a set-aside designation and represents a task order under the company's existing Blanket Purchase Agreement for Jynarque on the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract performance location is Pittsburgh, Pennsylvania. Jynarque (tolvaptan) is a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia, addressing a critical treatment need within the VA healthcare system.
This delivery order is part of Otsuka America Pharmaceutical Inc.'s broader relationship with the VA, wherein the company maintains significant indefinite delivery vehicles including an $83.3 million blanket purchase agreement for Jynarque that extends through March 2026 and a $396 million Federal Supply Schedule contract for pharmaceuticals and hematology products. These vehicles enable VA facilities across multiple Integrated Service Networks to procure specialized pharmaceutical treatments efficiently, supporting the agency's mission to provide comprehensive healthcare services to veterans nationwide. The award reflects Otsuka America Pharmaceutical Inc.'s established status as a qualified supplier of complex pharmaceutical products to federal healthcare systems.
Quick answers
Who was awarded contract 36C24622F0094?
36C24622F0094 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 6 (Veterans Health Administration) on December 30, 2021.
How much is contract 36C24622F0094 worth?
The government has obligated $136,002 on 36C24622F0094.
Is contract 36C24622F0094 an order under another contract?
Yes. 36C24622F0094 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24622F0094 competed?
The extent of competition for 36C24622F0094 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award